论文部分内容阅读
目的观察文拉法新联合多虑平治疗腹泻型肠易激综合征(IBS)的临床疗效。方法将54例IBS患者随机分为治疗组28例和对照组26例。对照组口服文拉法新胶囊,从50 mg/d起加量至(75～175)mg/d;治疗组同时加服小剂量多虑平,25 mg/d,2次/d。疗程4周。结果治疗组总有效率达64.3%,明显高于对照组的42.3%(P<0.05),同时在消化道症状评分、焦虑及抑郁程度评分方面,治疗组也明显优于对照组(P<0.05)。结论文拉法新联合小剂量多虑平治疗IBS具有协同作用,值得临床推广。
Objective To observe the clinical efficacy of venlafaxine and doxepin in the treatment of diarrhea-predominant irritable bowel syndrome (IBS). Methods 54 patients with IBS were randomly divided into treatment group 28 cases and control group 26 cases. The control group was given oral venlafaxine in increments of 50 mg / d to 75-175 mg / d. The treatment group was given low dose doxepin, 25 mg / d twice daily. Treatment for 4 weeks. Results The total effective rate of the treatment group was 64.3%, which was significantly higher than that of the control group (42.3%, P <0.05), and the treatment group was also significantly better than the control group in the score of gastrointestinal symptoms, anxiety and depression ). Conclusions Venlafaxine combined with low-dose doxepin in the treatment of IBS has a synergistic effect and is worthy of clinical promotion.